ERBB3 and prostate cancer: Stromal ASPN expression was observed in 82% of prostate cancer metastases, and over 50% of metastases were low/ultralow for both HER2 and HER3 and had stromal ASPN expression (Figure 8, A and H–L, and Supplemental Figure 6D).